The company provides medical testing services including pathology, radiology, and cardiology through a network of laboratories and diagnostic centers primarily in Northern India.
The company lacks a durable moat as evidenced by a low average ROCE of 11.4% and net margins that fell from 11.4% to 6.2% in the latest year despite revenue growth. While they have local brand recognition in Haryana, the diagnostic market is highly fragmented with low switching costs and intense price competition from digital aggregators.
Capital has been primarily directed toward aggressive physical expansion and medical equipment procurement funded by IPO proceeds and debt. However, the sharp decline in profitability and negative average ROE suggest that recent reinvestments have not yet yielded efficient returns for shareholders.
The business collapsed under the weight of aggressive physical expansion that failed to generate incremental returns. While revenue grew, the combination of intense price competition from digital aggregators and rising fixed costs eroded EBITDA margins from 24% to single digits. The company became a 'treadmill' business where every rupee of profit was consumed by the need for newer medical equipment and interest payments on rising debt. Eventually, the high concentration in Haryana left them vulnerable to a regional price war, and the stale receivables—already a red flag in the filings—proved uncollectible, leading to a liquidity crunch that wiped out shareholder equity.
RichFakir rates Modern Diagnostic & Research Centre Ltd's business quality as poor — 33/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Modern Diagnostic & Research Centre Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Modern Diagnostic & Research Centre Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Modern Diagnostic & Research Centre Ltd's fair value is about ₹25 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →